This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Tobacco  • Cardiovascular System  • Statistics and Research Methods  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their observational study, Dr Ho and colleagues¹ attributed a 9% increase in adverse outcomes to the attenuation of the benefit of clopidogrel through an interaction with PPIs. This exceeds by 400% the benefits of clopidogrel seen in the CURE trial² and is consistent with the extreme unbalancing in measured covariates observed between the groups. Only measured covariates can be corrected at the analytical level, and it seems likely that residual confounding is present. Supporting this contention, the clopidogrel benefit in CURE was observed within 60 days, but the negative differences in the study by Ho et al were apparent only at a much later time. This is when residual confounders may have exerted their influence and is outside the benefit window currently attributed to clopidogrel after ACS.

The primary analysis involved logistic regression and therefore assumes an approximately constant follow-up time, which was not met (interquartile . . . [Full Text of this Article]

Verena Schneider-Lindner, MD, MSc; Kristian B. Filion, MSc; James M. Brophy, MD, PhD
james.brophy@mcgill.ca
Department of Epidemiology, Biostatistics, and Occupational Health
McGill University
Montreal, Quebec, Canada

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
, , , , , , and
JAMA. ;301():937-944.
FULL TEXT  

RELATED LETTERS

Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
and
JAMA. ;302():29-29.
FULL TEXT  

Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel
and
JAMA. ;302():30-30.
FULL TEXT  

Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel

JAMA. ;302():30-31.
FULL TEXT  

Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel--Reply
, , and
JAMA. ;302():31-31.
FULL TEXT